A two-day nutraceutical intervention (Qualia Senolytic) significantly reduced senescence-associated chemokines CXCL9 and CXCL10, along with CCL8 and CXCL11, in 53 healthy adults aged 45-79. These chemokines are key drivers of chronic inflammation that accumulates with cellular senescence, the process where damaged cells stop dividing but continue secreting harmful inflammatory compounds. The "hit-and-run" approach mirrors emerging senolytic research suggesting brief interventions may be more effective than continuous supplementation for clearing senescent cells. This represents an intriguing departure from traditional supplement protocols that emphasize daily dosing. However, the study's single-arm design without placebo control severely limits interpretation—the observed changes could reflect natural fluctuation, measurement error, or placebo effects. The failure to move primary endpoints (TNF, IL-1β, IL-8, VEGFA) while showing effects on secondary markers raises questions about selective reporting. Quality of life improvements in an unblinded study are particularly suspect. While the chemokine reductions align with theoretical senolytic mechanisms, this preliminary finding requires rigorous placebo-controlled validation before drawing meaningful conclusions about anti-aging efficacy.